Deutsche Bank analyst George Hill lowered the firm’s price target on GoodRx (GDRX) to $3 from $6 and keeps a Hold rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx price target lowered to $3 from $6 at TD Cowen
- GoodRx price target lowered to $2 from $4 at UBS
- Balancing Near-Term Headwinds and Long-Term Growth: Justifying a Buy/High-Risk Rating on Pharma Direct-Led Upside
- GoodRx price target lowered to $3 from $4 at Mizuho
- GoodRx downgraded to Neutral from Overweight at JPMorgan